NasdaqGS - Nasdaq Real Time Price USD

Spero Therapeutics, Inc. (SPRO)

Compare
0.9551 -0.0429 (-4.30%)
At close: December 20 at 4:00:01 PM EST
0.9539 -0.00 (-0.13%)
After hours: December 20 at 4:15:04 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
89,865.0000
96,735.0000
48,579.0000
3,070.0000
258.0000
Operating Expense
90,969.0000
69,948.0000
79,146.0000
91,041.0000
79,371.0000
Operating Income
-1,104.0000
26,787.0000
-30,567.0000
-87,971.0000
-79,113.0000
Net Non Operating Interest Income Expense
4,750.0000
3,937.0000
-1,499.0000
-1,594.0000
401.0000
Other Income Expense
-36.0000
-5,320.0000
-14,349.0000
-191.0000
432.0000
Pretax Income
3,610.0000
25,404.0000
-46,415.0000
-89,756.0000
-78,280.0000
Tax Provision
97.0000
2,598.0000
--
--
--
Net Income Common Stockholders
3,513.0000
22,806.0000
-46,415.0000
-89,756.0000
-78,280.0000
Diluted NI Available to Com Stockholders
3,513.0000
22,806.0000
-46,415.0000
-89,756.0000
-78,280.0000
Basic EPS
0.08
0.43
-1.23
-2.91
-3.52
Diluted EPS
0.08
0.43
-1.23
-2.91
-3.52
Basic Average Shares
53,653.0530
52,703.4670
37,585.0750
30,895.7560
22,386.1220
Diluted Average Shares
53,938.6160
52,989.0300
37,585.0750
30,895.7560
22,386.1220
Total Operating Income as Reported
-1,104.0000
21,481.0000
-42,197.0000
-87,971.0000
-79,113.0000
Total Expenses
90,969.0000
69,948.0000
79,146.0000
91,041.0000
79,371.0000
Net Income from Continuing & Discontinued Operation
3,513.0000
22,806.0000
-46,415.0000
-89,756.0000
-78,280.0000
Normalized Income
3,513.0000
27,570.7880
-35,702.0000
-89,960.0000
-78,280.0000
Interest Income
4,750.0000
3,937.0000
1,106.0000
346.0000
401.0000
Interest Expense
4,545.0000
--
2,605.0000
1,940.0000
--
Net Interest Income
4,750.0000
3,937.0000
-1,499.0000
-1,594.0000
401.0000
EBIT
-2,487.0000
25,404.0000
-43,810.0000
-87,816.0000
-78,280.0000
EBITDA
-2,447.0000
25,771.0000
-42,941.0000
-87,170.0000
-77,519.0000
Reconciled Depreciation
40.0000
367.0000
869.0000
646.0000
761.0000
Net Income from Continuing Operation Net Minority Interest
3,513.0000
22,806.0000
-46,415.0000
-89,756.0000
-78,280.0000
Total Unusual Items Excluding Goodwill
--
-5,306.0000
-10,713.0000
204.0000
--
Total Unusual Items
--
-5,306.0000
-10,713.0000
204.0000
--
Normalized EBITDA
-2,447.0000
31,077.0000
-32,228.0000
-87,374.0000
-77,519.0000
Tax Rate for Calcs
0.0000
0.0001
--
--
--
Tax Effect of Unusual Items
--
-541.2120
--
--
--
12/31/2020 - 11/2/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CTMX CytomX Therapeutics, Inc.
1.0900
-0.91%
 
ASMB Assembly Biosciences, Inc.
15.21
-3.80%
 
HLVX HilleVax, Inc.
1.8600
+1.64%
 
GLTO Galecto, Inc.
4.7000
+0.43%
 
NXTC NextCure, Inc.
0.9700
+2.11%
 
ANTX AN2 Therapeutics, Inc.
1.2600
-0.79%
 
EPIX ESSA Pharma Inc.
1.6000
0.00%
 
SEER Seer, Inc.
2.3100
-0.43%
 
CLRB Cellectar Biosciences, Inc.
0.2350
-1.26%
 
IPSC Century Therapeutics, Inc.
1.1000
+4.76%